Skip to content

Reviva Pharmaceuticals Holdings, Inc.: 10-K filed 2024-04-15

What Reviva Pharmaceuticals Holdings, Inc. reported in its annual report filed 2024-04-15 (fiscal FY 2023): 28 published measures, 112 facts as tagged in accession 0001437749-24-011955.

This filing

Form
10-K (annual report)
Filed
2024-04-15
Fiscal period
fiscal FY 2023
Accession
0001437749-24-011955 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Reviva Pharmaceuticals Holdings, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-12-3123,700,388USD
At 2022-12-3118,923,675USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-12-3117,981,672USD
At 2023-09-3018,197,762USD
At 2023-06-3013,657,217USD
At 2023-03-3111,287,846USD
At 2022-12-3110,529,429USD
At 2022-09-306,485,121USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-12-315,718,716USD
At 2023-09-30-12,810,721USD
At 2023-06-30-1,815,195USD
At 2023-03-311,613,677USD
At 2022-12-318,394,246USD
At 2022-09-3017,555,829USD
At 2021-12-3128,686,460USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-12-3123,367,456USD
At 2022-12-3118,519,856USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-39,260,837USD365
2023-07-01 to 2023-09-30-11,345,936USD92
2023-01-01 to 2023-09-30-29,905,573USD273
2023-04-01 to 2023-06-30-11,707,948USD91
2023-01-01 to 2023-06-30-18,559,637USD181
2023-01-01 to 2023-03-31-6,851,689USD90
2022-01-01 to 2022-12-31-28,261,442USD365
2022-07-01 to 2022-09-30-5,450,270USD92
2022-01-01 to 2022-09-30-19,024,710USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-28,324,353USD365
2023-01-01 to 2023-09-30-19,447,908USD273
2023-01-01 to 2023-06-30-13,268,624USD181
2023-01-01 to 2023-03-31-7,951,397USD90
2022-01-01 to 2022-12-31-18,960,581USD365
2022-01-01 to 2022-09-30-14,269,947USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-12-3133,171,953USD365
2022-01-01 to 2022-12-317,792,493USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-12-31-134,354,248USD
At 2023-09-30-124,998,984USD
At 2023-06-30-113,653,048USD
At 2023-03-31-101,945,100USD
At 2022-12-31-95,093,411USD
At 2022-09-30-85,856,679USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-01-01 to 2023-12-3123,798,203shares365
2022-01-01 to 2022-12-3119,516,479shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-1.65USD/shares365
2023-07-01 to 2023-09-30-0.48USD/shares92
2023-01-01 to 2023-09-30-1.32USD/shares273
2023-04-01 to 2023-06-30-0.52USD/shares91
2023-01-01 to 2023-06-30-0.84USD/shares181
2023-01-01 to 2023-03-31-0.31USD/shares90
2022-01-01 to 2022-12-31-1.45USD/shares365
2022-07-01 to 2022-09-30-0.28USD/shares92
2022-01-01 to 2022-09-30-1.02USD/shares273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-01-01 to 2023-12-3116,949USD365
2022-01-01 to 2022-12-3120,777USD365

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-01-01 to 2023-12-313,413,354USD365
2022-01-01 to 2022-12-31176,735USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-39,503,636USD365
2023-07-01 to 2023-09-30-11,563,954USD92
2023-01-01 to 2023-09-30-29,884,290USD273
2023-04-01 to 2023-06-30-11,335,637USD91
2023-01-01 to 2023-06-30-18,320,336USD181
2023-01-01 to 2023-03-31-6,984,699USD90
2022-01-01 to 2022-12-31-28,228,758USD365
2022-07-01 to 2022-09-30-5,497,915USD92
2022-01-01 to 2022-09-30-19,336,288USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-12-3117,175,017USD
At 2023-09-3017,324,351USD
At 2023-06-3012,644,727USD
At 2023-03-3110,731,533USD
At 2022-12-319,961,990USD
At 2022-09-306,379,422USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-12-313,849,108USD
At 2022-12-313,520,271USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-01-01 to 2023-12-3139,503,636USD365
2023-07-01 to 2023-09-3011,563,954USD92
2023-01-01 to 2023-09-3029,884,290USD273
2023-04-01 to 2023-06-3011,335,637USD91
2023-01-01 to 2023-06-3018,320,336USD181
2023-01-01 to 2023-03-316,984,699USD90
2022-01-01 to 2022-12-3128,228,758USD365
2022-07-01 to 2022-09-305,497,915USD92
2022-01-01 to 2022-09-3019,336,288USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-01-01 to 2023-12-3131,419,817USD365
2023-07-01 to 2023-09-309,572,180USD92
2023-01-01 to 2023-09-3023,312,661USD273
2023-04-01 to 2023-06-308,256,336USD91
2023-01-01 to 2023-06-3013,740,481USD181
2023-01-01 to 2023-03-315,484,145USD90
2022-01-01 to 2022-12-3122,870,024USD365
2022-07-01 to 2022-09-304,240,943USD92
2022-01-01 to 2022-09-3015,454,078USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-12-3127,918,560shares
At 2022-12-3120,447,371shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-12-31140,070,172USD
At 2022-12-31103,485,612USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2023-12-31332,932USD
At 2022-12-31403,819USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2023-12-310USD
At 2022-12-310USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-39,243,888USD365
2022-01-01 to 2022-12-31-28,240,665USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-01-01 to 2023-12-318,083,819USD365
2022-01-01 to 2022-12-315,358,734USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-01-01 to 2023-12-31259,748USD365
2022-01-01 to 2022-12-31-11,907USD365

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2023-01-01 to 2023-12-3116,949USD365
2022-01-01 to 2022-12-3120,777USD365

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2023-01-01 to 2023-12-310USD365
2022-01-01 to 2022-12-310USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-01-01 to 2023-12-3130,622USD365
2022-01-01 to 2022-12-310USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-12-31328,837USD365
2022-01-01 to 2022-12-313,010,688USD365

Inspect the source

Entity
Reviva Pharmaceuticals Holdings, Inc. / CIK 0001742927
Captured
2026-09-19T11:20:56.685Z
SEC response SHA-256
26f740ff1a169faebcba46f28197dc15a1be7bab2feb9b4952e7b7f15df066e6

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001742927.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))